Business

Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business Highlights

-- Zola® revenues increase 17% year-over-year -- -- Arcadia and Roosevelt Resources terminate proposed business combination -- -- Exercise of preferred

articleArcadia Biosciences, Inc.March 26, 20265/company/arcadia-biosciences-inc/news/arcadia-biosciences-rkda-announces-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business Highlights

About this update from Arcadia Biosciences, Inc.

[{"type":"text","content":"-- Zola® revenues increase 17% year-over-year -- -- Arcadia and Roosevelt Resources terminate proposed business combination -- -- Exercise of preferred investment options yields $2.1 million gross proceeds -- DALLAS, March 26, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the fourth quarter and full year of 2025. “At the end of 2025, we received a termination notice from Roosevelt Resources related to the Securities Exchange Agreement concerning a proposed business combination, signed in December 2024.” said T.J. Schaefer, CEO of Arcadia. Schaefer continued, “After receiving this news, we took steps to improve our balance sheet by entering into definitive agreements for the immediate exercise of certain outstanding preferred investment options, resulting in gross proceeds of approximately $2.1 million to Arcadia. We intend to use these proceeds, along with our other assets, to continue growing our Zola® coconut water brand while we evaluate strategic alternatives. “In 2025, Zola sales growth continued to outpace the coconut water category. At the same time, we reduced our SG&A expenses by approximately 27%, and our net cash used in operating activities declined by 49% in 2025 compared to 2024,” Schaefer added. Arcadia Biosciences, Inc.Financial Snapshot(Unaudited)($ in thousands) Three months ended Dec 31 Twelve months ended Dec 31 2025 2024 Favorable/(Unfavorable) 2025 2024 Favorable/(Unfavorable) $% $%Total Revenues901 1,216 (315)(26%) 4,858 5,045 (187)(4%)Total Operating Expenses2,276 3,495 1,219 35% 7,358 8,693 1,335 15%Loss From Continuing Operations(1,375)(2,279)904 40% (2,500)(3,648)1,148 31%Net Loss Attributable to Common Stockholders(1,336)(4,064)2,728 67% (2,339)(7,038)4,699 67% Certain previously reported financial information has been reclassified to conform to the current year presentation. Reclassifications are related to the presentation of the financial results of our former GoodWheat™ brand as discontinued operations. The financial information above and narrative that follows relate to continuing operations unless stated otherwise. More detailed financial statements are included in the Form 8-K filed today, available in the Investors section of the company’s website under SEC Filin...

More updates from Arcadia Biosciences, Inc.